文献速递乳腺胸部CT

全乳放疗后二次癌症风险:分野放疗对比调强放疗对比容积旋转调强放疗

Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy.
PubMed 文献 · Br J Radiol · 2019-07-22

基于12例患者CT数据生成三种全乳放疗计划(50 Gy/2 Gy分次),采用器官等效剂量概念评估对侧乳腺、对侧肺和同侧肺的二次癌症超额绝对风险。分野放疗的二次癌症风险显著低于调强放疗和容积旋转调强放疗,当二次癌症风险为主要顾虑时作者认为分野放疗是首选治疗方式。

要点

  • 分野放疗对侧乳腺、对侧肺和同侧肺的超额绝对风险均最低。
  • 分野放疗较调强放疗分别降低对侧乳腺、对侧肺和同侧肺风险77%、88%和56%。
  • 调强放疗与容积旋转调强放疗的对侧乳腺和同侧肺风险相似。

核心结论

  • 总体超额绝对风险评估显示,全乳放疗的辐射诱发癌症风险分野放疗低于调强放疗和容积旋转调强放疗;当二次癌症风险为主要顾虑时,作者认为分野放疗是全乳照射的首选治疗方式。

研究设计与样本

  • 基于12例患者CT数据集生成三种全乳放疗计划,处方剂量50 Gy、2 Gy分次:三维适形分野放疗技术、调强放疗和容积旋转调强放疗。

诊断标准与关键数值

  • 器官等效剂量基于「线性-指数」「平台」和「全机制」三种剂量-反应模型从微分剂量-体积直方图计算。
  • 分野放疗较调强放疗降低超额绝对风险:对侧乳腺77%、对侧肺88%、同侧肺56%。
  • 分野放疗较容积旋转调强放疗降低超额绝对风险:对侧乳腺77%、对侧肺84%、同侧肺58%。
  • 对侧乳腺和同侧肺的器官等效剂量二次癌症风险在调强放疗与容积旋转调强放疗之间相似。
  • 对侧肺风险在使用容积旋转调强放疗时统计学上更低。

临床应用与阅片要点

  • 当二次癌症风险为主要顾虑时,作者认为分野放疗是全乳照射的首选治疗方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: In this study, we used the concept of organ-equivalent dose (OED) to evaluate the excess absolute risk (EAR) for secondary cancer in various organs after radiation treatment for breast cancer.

METHODS: Using CT data set of 12 patients, we generated three different whole-breast radiation treatment plans using 50 Gy in 2 Gy fractions: three-dimensional conformal radiotherapy with a field-in-field (FinF) technique, intensity modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT). The OEDs were calculated from differential dose-volume histograms on the basis of the "linear-exponential," "plateau," and "full mechanistic" dose-response models. Secondary cancer risks of the contralateral breast (CB), contralateral lung (CL), and ipsilateral lung (IL) were estimated and compared.

RESULTS: The lowest EARs for the CB, CL, and IL were achieved with FinF, which reduced the EARs by 77%, 88%, and 56% relative to those with IMRT, and by 77%, 84%, and 58% relative to those with VMAT, respectively. The secondary cancer risk for FinF was significantly lower than those of IMRT and VMAT. OED-based secondary cancer risks for CB and IL were similar when IMRT and VMAT were used, but the risk for CL was statistically lower when VMAT was used.

CONCLUSION: The overall estimation of EAR indicated that the radiation-induced cancer risk of breast radiation therapy was lower with FinF than with IMRT and VMAT. Therefore, when secondary cancer risk is a major concern, FinF is considered to be the preferred treatment option in irradiation of whole-breast.

ADVANCES IN KNOWLEDGE: Secondary malignancy estimation after breast radiotherapy is becoming an important subject for comparative treatment planning.When secondary cancer risk a major concern, FinF technique is considered the preferred treatment option in whole breast patients.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Haciislamoglu E, Cinar Y, Gurcan F, et al. Secondary cancer risk after whole-breast radiation therapy: field-in-field versus intensity modulated radiation therapy versus volumetric modulated arc therapy. Br J Radiol. 2019. PMID: 31295011. doi:10.1259/bjr.20190317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。